EUVIMEDEUVIMED entdecken
Crossref

Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer

Syeda Abida Ejaz iD, Muhammad Sajjad Bilal, Mubashir Aziz, Tanveer A Wani, Seema Zargar, Ammara Fayyaz, Sidra Hassan, Aftab Ahmed, Hammad M Al Kahtani, Farhan Siddique

Chemistry & Biodiversity · 2023

DOI: 10.1002/cbdv.202301190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Syeda Abida Ejaz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacv, The Islamia University of, Bahawalpur, 63100, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Deputyship for Research and Innovation, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Epidermal Growth Factor Receptor (EGFR) is an important therapeutic target for the treatment of a variety of epithelial malignancies, including breast cancer, in which EGFR is aberrantly expressed.The fluorocyclopentenyl‐purine‐pyrimidines derivatives, which have previously been described as powerful compounds against breast cancer, were selected to investigate their potential against EGFR using computational tools in an effort to obtain potent inhibitors with fewer adverse effects. The molecule's chemical reactivity and stability were assessed by determining the HOMO‐LUMO energy gap using density functional theory (DFT) calculations. Among all the selected compounds, PU4 displayed a HOMO‐LUMO gap of 0.191 eV. Additionally, molecular docking analysis was performed to assess the binding affinities of PU4 within the active pocket of EGFR‐TK. The compound PU4 showed potent interactions with EGFR exhibiting −32.3 kJ/mol binding energy which was found best as compared to gefitinib i. e., −27.4 kJ/mol which was further validated by molecular dynamics simulations and ADMET analysis. The results of these analyses indicate that the top hits obtained from the virtual screening possess the ability to act as effective EGFR inhibitor. Therefore, it is recommended to further investigate the inhibitory potential of these identified compounds using in vitro and in vivo approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMolecular Docking SimulationProtein Kinase InhibitorsErbB ReceptorsMolecular Dynamics SimulationPurinesPyrimidines

Stichwörter der Autor:innen

DFTEGFRMD simulationfluorocyclopentenyl-purinemolecular docking

Substanzen

Protein Kinase InhibitorsErbB ReceptorsPurinesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacv, The Islamia University of, Bahawalpur, 63100, Pakistan.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
  • Department of Biochemistry, College of Science, King Saud University, P.O. Box, 22452, Riyadh 11451, Saudi Arabia.
  • Bahawalpur College of Pharmacy, Bahawalpur Medical and Dental College, Bahawalpur, Pakistan.
  • Department of Pharmacy, Royal Institute of Medical Sciences (RIMS) Multan 60000, Pakistan.
  • Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 79409-1061, USA.

ORCID-Profile: Syeda Abida Ejaz

Förderung

  • Deputyship for Research and Innovation, Ministry of Education

Zitieren

APA

Abida Ejaz, S., Sajjad Bilal, M., Aziz, M., Wani, T. A., Zargar, S., Fayyaz, A., Hassan, S., Ahmed, A., Al Kahtani, H. M., & Siddique, F. (2023). Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301190

Vancouver

Abida Ejaz S, Sajjad Bilal M, Aziz M, Wani TA, Zargar S, Fayyaz A, et al. Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301190

BibTeX
@article{AbidaEjaz2023,
  author = {Abida Ejaz, Syeda and Sajjad Bilal, Muhammad and Aziz, Mubashir and Wani, Tanveer A and Zargar, Seema and Fayyaz, Ammara and Hassan, Sidra and Ahmed, Aftab and Al Kahtani, Hammad M and Siddique, Farhan},
  title = {Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer},
  journal = {Chemistry & Biodiversity},
  year = {2023},
  doi = {10.1002/cbdv.202301190}
}
Kostenlos starten →